Glythera relocates to North East as part of funding round  

Glythera, an emerging biopharmaceutical company specialising in protein/peptide functionalisation and glycosylation, has secured a fundraising round totalling £2M with IP Group, which will be tranched over the next three years.

The University of Bath spin-out has established commercial operations at Newcastle’s INEX incubator facility, following an initial £600,000 investment split equally between IP Group and its managed fund, the Finance for Business North East Technology Fund. The next two tranches will be of a similar size and are contingent on certain milestones being met.

Glythera’s relocation has created new research and development positions in the North East of England and Dr David Simpson, who has over 15 years experience in the biopharmaceutical industry has joined as Chief Operating Officer. Further growth is anticipated over the next three years in line with the company’s commercial and technical needs.

Dr Anthony Baxter, Glythera’s Chairman, commented: “We are obviously delighted to close this funding round in what remains a challenging environment. Our ability to do this is testament to the strength of the Glythera technology, combined with the leadership and technical skills of our team.”

David added: “Relocating to the North East makes a lot of sense for us, due to the region’s strong pedigree in biomanufacturing, giving us the ideal base from which to partner with leading companies and attract a skilled workforce.”

Duncan Lowery, Senior Investment Manager at IP Group also added: " With a revolutionary product and extremely experienced management team, we’re confident that Glythera will hit its targets and continue to build a reputation as a rising star within the pharmaceutical industry.”